These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 15592323)
1. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323 [TBL] [Abstract][Full Text] [Related]
2. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850 [TBL] [Abstract][Full Text] [Related]
3. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495 [TBL] [Abstract][Full Text] [Related]
5. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Ho MK; Mwenifumbo JC; Zhao B; Gillam EM; Tyndale RF Pharmacogenet Genomics; 2008 Jan; 18(1):67-75. PubMed ID: 18216723 [TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Peamkrasatam S; Sriwatanakul K; Kiyotani K; Fujieda M; Yamazaki H; Kamataki T; Yoovathaworn K Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563 [TBL] [Abstract][Full Text] [Related]
7. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137 [TBL] [Abstract][Full Text] [Related]
8. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Kwon JT; Nakajima M; Chai S; Yom YK; Kim HK; Yamazaki H; Sohn DR; Yamamoto T; Kuroiwa Y; Yokoi T Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509 [TBL] [Abstract][Full Text] [Related]
9. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Paschke T; Riefler M; Schuler-Metz A; Wolz L; Scherer G; McBride CM; Bepler G Toxicology; 2001 Nov; 168(3):259-68. PubMed ID: 11684323 [TBL] [Abstract][Full Text] [Related]
10. Novel human CYP2A6 alleles confound gene deletion analysis. Nakajima M; Yoshida R; Fukami T; McLeod HL; Yokoi T FEBS Lett; 2004 Jul; 569(1-3):75-81. PubMed ID: 15225612 [TBL] [Abstract][Full Text] [Related]
11. Determination of coumarin metabolism in Turkish population. Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269 [TBL] [Abstract][Full Text] [Related]
12. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685 [TBL] [Abstract][Full Text] [Related]
13. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802 [TBL] [Abstract][Full Text] [Related]
14. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041 [TBL] [Abstract][Full Text] [Related]
15. A novel duplication type of CYP2A6 gene in African-American population. Fukami T; Nakajima M; Yamanaka H; Fukushima Y; McLeod HL; Yokoi T Drug Metab Dispos; 2007 Apr; 35(4):515-20. PubMed ID: 17267622 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Yoshida R; Nakajima M; Watanabe Y; Kwon JT; Yokoi T Br J Clin Pharmacol; 2002 Nov; 54(5):511-7. PubMed ID: 12445030 [TBL] [Abstract][Full Text] [Related]
17. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Mwenifumbo JC; Lessov-Schlaggar CN; Zhou Q; Krasnow RE; Swan GE; Benowitz NL; Tyndale RF Clin Pharmacol Ther; 2008 Jan; 83(1):115-21. PubMed ID: 17522595 [TBL] [Abstract][Full Text] [Related]
18. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Inoue K; Yamazaki H; Shimada T Arch Toxicol; 2000 Jan; 73(10-11):532-9. PubMed ID: 10663384 [TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Oscarson M; McLellan RA; Asp V; Ledesma M; Bernal Ruiz ML; Sinues B; Rautio A; Ingelman-Sundberg M Hum Mutat; 2002 Oct; 20(4):275-83. PubMed ID: 12325023 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Al Koudsi N; Mwenifumbo JC; Sellers EM; Benowitz NL; Swan GE; Tyndale RF Eur J Clin Pharmacol; 2006 Jun; 62(6):481-4. PubMed ID: 16758265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]